Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7031082 | 1.00 | HDAC3 (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6309258 | 0.79 | PIK3CD (0.40) | CYP19A1 | |
| SCHEMBL7537691 | 0.79 | PIK3CD (0.40) | CYP19A1 | |
| SCHEMBL6369317 | 0.75 | KMT2A (0.30) | — | |
| SCHEMBL6301634 | 0.75 | KMT2A (0.30) | — | |
| SCHEMBL8958844 | 0.63 | CYP3A4 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7031086 | 0.63 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL6846167 | 0.63 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL9558633 | 0.62 | PRCP (0.31) | KDM4E | |
| SCHEMBL1682219 | 0.60 | CYP3A4 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248878-A1 | Lactam compound | KOENIG THOMAS MITCHELL (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040077627-A1 | Lactam compound | KOENIG THOMAS MITCHELL (US) | 2004-04-22 | — | — | US | disclosed |
| EP-1353910-A2 | LACTAM COMPOUND | ELI LILLY AND COMPANY (US) | 2003-10-22 | — | — | EP | disclosed |
| EP-1345955-A2 | LACTAM DIPEPTIDE AND ITS USE IN INHIBITING BETA-AMYLOID PEPTIDE RELEASE | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002040451-A2 | LACTAM COMPOUND | ELI LILLY AND COMPANY (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040508-A2 | LACTAM DIPEPTIDE AND ITS USE IN INHIBITING BETA-AMYLOID PEPTIDE RELEASE | ELI LILLY AND COMPANY (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077627-A1 | Lactam compound | AAAS, BCHE, CHLSN | HDAC3 399/4885HDAC4 411/4885HDAC1 371/4885 |
| US-20040248878-A1 | Lactam compound | AAAS, CHLSN, APH1B | HDAC3 400/4885HDAC4 612/4885HDAC1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.